Clinical and economic impact of high short-acting β-agonist use in patients with persistent asthma

Includes bibliographical references. ; Summer ; High Short-Acting β−Agonists (SABA) use is an important indicator of poor asthma control and has been utilized in various studies as a proxy measure of asthma control for various purposes (e.g. predictive marker for future exacerbation events). However, little evidence exists with regard to the optimal measurement of high SABA use for predicting future exacerbation events as well as the impact of asthma control, as measured by high SABA use and other characteristics, on Health Related Quality of Life (HRQoL) and Health Resource Utilization (HRU).... Mehr ...

Verfasser: Kim, Chong Hoon
Dokumenttyp: Text
Erscheinungsdatum: 2020
Verlag/Hrsg.: University of Colorado at Denver
Anschutz Medical Campus. Health Sciences Library
Schlagwörter: Database analysis / HRU / SABA / Economics / Pharmaceutical / Asthma / Quality of Life
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26889425
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/10968/5746